[A23-37] Cemiplimab (NSCLC, combination with platin-based chemotherapy) - Benefit assessment according to §35a Social Code Book V

Last updated 01.08.2023

Project no.:
A23-37

Commission:
Commission awarded on 28.04.2023 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer

Indication:

First-line treatment of adult patients with non-small cell lung cancer (NSCLC) with no epidermal growth factor receptor, anaplastic lymphoma kinase or c-ros oncogene 1 aberrations, who have locally advanced NSCLC who are not candidates for definitive chemoradiation, or who have metastatic NSCLC.

Result of dossier assessment:
  • Patients with PD-L1 expression in ≥ 50% of tumour cells: added benefit not proven
  • Patients with PD-L1 expression in ≥ 1 % to < 50 % of tumour cells: added benefit not proven
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form